Summary
Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a research-based pharmaceutical company, which carries out the discovery, production and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes pharmaceuticals for the treatment of diseases such as type II diabetes, overactive bladder, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. Ono Pharmaceutical also has many other products in pipeline development. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusion. It has operational presence in Japan, Taiwan, South Korea, the UK and the US. Ono Pharmaceutical is headquartered in Chuo-ku, Osaka, Japan.
Ono Pharmaceutical Co Ltd (4528) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Receptos Expands Collaboration With Ono Pharma For GPCR Technology Platform 17
Seikagaku Enters into Partnership with Ono Pharmaceutical 18
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 19
X-Chem Enters into Agreement with Ono Pharma 19
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 20
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 21
Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 23
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 24
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 25
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 26
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 27
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 28
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 29
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 30
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 31
Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 31
Receptos Enters Into R&D Agreement With Ono Pharma 32
Progenra Enters Into Research Agreement With Ono Pharma 33
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 34
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 36
Ono Pharma Extends Research Agreement With Evotec 37
Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex 38
Xention Extends Collaboration With Ono Pharma 39
Ono Pharma Enters Into Co-Development Agreement With BioFocus 40
Licensing Agreements 40
Ono Pharma Enters into Licensing Agreement with Array BioPharma 40
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 41
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 43
ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 43
ONO Pharma Enters into Licensing Agreement with Celyad 44
Santen Pharma Enters into Licensing Agreement with Ono Pharma 45
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 46
Ono Pharma Enters into Licensing Agreement with Merus 47
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 48
Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 49
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 49
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 51
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 52
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 52
Ono Pharma Enters Into Licensing Agreement With OncoTherapy 54
Ono Pharmaceutical Co Ltd - Key Competitors 55
Key Employees 56
Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Recent Developments 60
Strategy And Business Planning 60
Mar 01, 2016: Completion of the new Research Building (The Third Building) in the Minase Research Institute 60
Financial Announcements 61
Dec 21, 2016: ONO PHARMACEUTICAL: Revisions of Consolidated Financial Forecasts 61
Government and Public Interest 62
Jul 27, 2016: Infusion of Nearly $35.4 Million in Grant Funding to Support Roswell Park Research 62
Product News 64
Jan 26, 2016: ONO PHARMACEUTICAL Selects Medidata to Power Clinical Trials Exploring Additional Cancer Indications for Immunotherapy Drug OPDIVO 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Tables
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 1
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Ono Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Receptos Expands Collaboration With Ono Pharma For GPCR Technology Platform 17
Seikagaku Enters into Partnership with Ono Pharmaceutical 18
Numab Therapeutics Enters into Research and Option Agreement with Ono Pharma 19
X-Chem Enters into Agreement with Ono Pharma 19
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 20
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 21
Ono Pharma Enters into Development Agreement with China Chemical & Pharma for Limaprost Alfadex 23
Dako Enters into Development Agreement with ONO PHARMA for Opdivo 24
Ono Pharma Enters into Development Agreement with Meiji Seika for Limaprost Alfadex 25
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 26
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 27
Ono Pharma Expands Co -Development Agreement With Dainippon Sumitomo Pharma For Limaprost Alfadex 28
Ono Pharma Enters Into Drug Discovery Agreement With Domain Therapeutics 29
Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 30
Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 31
Ono Pharma Enters Into Co-Development Agreement With Scil Proteins For Affilin Therapeutics 31
Receptos Enters Into R&D Agreement With Ono Pharma 32
Progenra Enters Into Research Agreement With Ono Pharma 33
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma 34
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA 36
Ono Pharma Extends Research Agreement With Evotec 37
Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex 38
Xention Extends Collaboration With Ono Pharma 39
Ono Pharma Enters Into Co-Development Agreement With BioFocus 40
Ono Pharma Enters into Licensing Agreement with Array BioPharma 40
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 41
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 43
ONO Pharma Enters into Licensing Agreement with IDAC Theranostics 43
ONO Pharma Enters into Licensing Agreement with Celyad 44
Santen Pharma Enters into Licensing Agreement with Ono Pharma 45
Ono Pharma Enters into Licensing Agreement with Gilead Sciences for ONO-4059 46
Ono Pharma Enters into Licensing Agreement with Merus 47
Ono Pharma Enters Into Licensing Agreement With Bial For BIA 9-1067 48
Ono Pharma Enters Into Licensing Agreement With Genedata For Genedata Expressionist 49
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 49
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 51
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169 52
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine 52
Ono Pharma Enters Into Licensing Agreement With OncoTherapy 54
Ono Pharmaceutical Co Ltd, Key Competitors 55
Ono Pharmaceutical Co Ltd, Key Employees 56
Ono Pharmaceutical Co Ltd, Other Locations 58
Ono Pharmaceutical Co Ltd, Subsidiaries 58List of Figures
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Ono Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Ono Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
